The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Speakers' Bureau - Lilly
Re-biopsy in advanced non-small cell lung cancer patients after the development of 3rd generation EGFR-TKI and new targeted therapies.
 
Kaname Nosaki
No Relationships to Disclose
 
Eiko Inamasu
No Relationships to Disclose
 
Shin-ichiro Shimamatsu
No Relationships to Disclose
 
Tsukihisa Yoshida
No Relationships to Disclose
 
Goji Toyokawa
Speakers' Bureau - Chugai Pharma; Pfizer
 
Fumihiko Hirai
Speakers' Bureau - Chugai Pharma; Kyowa Hakko Kirin; Novartis; Taiho Pharmaceutical
 
Masafumi Yamaguchi
Speakers' Bureau - Chugai Pharma; Lilly; Ono Pharmaceutical
 
Takashi Seto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Fuji Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Mitsuhiro Takenoyama
Speakers' Bureau - Chugai Pharma; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Yukito Ichinose
Speakers' Bureau - Chugai Pharma; KAKETSUKEN; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Taisho Toyama Pharma
Research Funding - Taiho Pharmaceutical (Inst); Takeda (Inst)